Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized multicenter platform study of mirikizumab in pediatric Crohn's disease
MOH_2024-01-16_013111Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of mirikizumab in Crohn's disease (4 arms), sponsored by Eli Lilly and Company. Started Dec 2023; status: recruiting.
02
Drugs
mirikizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2024-01-16_013111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-16_013111.